<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To evaluate the efficacy and safety of FOLFIRI regimen in patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> refractory to fluoropyrimidine and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The FOLFIRI regimen consisted of intravenous infusion of irinotecan 180 mg/m(2) on day 1 plus leucovorin (LV) 400 mg/m(2) on day 1 plus <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) 400 mg/m(2) bolus on day 1 plus 46-hour intravenous infusion of 5-FU 2,400 mg/m(2), every 2 weeks as one cycle </plain></SENT>
<SENT sid="2" pm="."><plain>The main selection criterion for this study was the advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> refractory to fluoropyrimidine and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Of the 57 evaluable patients for efficacy, 4 (7.5%) had a partial response, 36 (67.9%) had stable disease, and 13 (24.5%) had progressive disease </plain></SENT>
<SENT sid="4" pm="."><plain>Median progression-free survival was 4.8 months (95% CI 3.9-5.7 months), and median overall survival was 7.8 months (95% CI 13.1-16.5 months) </plain></SENT>
<SENT sid="5" pm="."><plain>Safety analysis was based on the data of 57 evaluable patients </plain></SENT>
<SENT sid="6" pm="."><plain>The most frequently observed grade 3 or 4 toxicities were <z:hpo ids='HP_0001875'>neutropenia</z:hpo> 16 (27.8%), <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo> 7 (12.3%), and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> 1 (1.8%) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: FOLFIRI regimen is effective and well tolerated in patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> refractory to fluoropyrimidine and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in Chinese population </plain></SENT>
</text></document>